|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:approves
|
gptkb:2004
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Truvada
|
|
gptkbp:can_be_combined_with
|
ART
Pr EP
other medications for HIV
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
HIV treatment
HIV prevention
|
|
gptkbp:contains
|
gptkb:tenofovir_disoproxil_fumarate
gptkb:emtricitabine
|
|
gptkbp:contraindication
|
renal impairment
hypersensitivity to components
|
|
gptkbp:dosage_form
|
oral tablet
|
|
gptkbp:form
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Truvada
|
|
gptkbp:ingredients
|
gptkb:tenofovir
gptkb:emtricitabine
|
|
gptkbp:interacts_with
|
other antiretroviral drugs
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_a_guide_for
|
gptkb:CDC
gptkb:WHO
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkb:Gilead_Sciences
|
|
gptkbp:patient_education
|
important for adherence
|
|
gptkbp:patient_population
|
adults
adolescents
high-risk individuals
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
inhibits reverse transcriptase
nucleotide analog
half-life of 17 hours
|
|
gptkbp:previous_name
|
yes
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
HIV treatment guidelines
HIV prevention guidelines
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:research_focus
|
gptkb:HIV/_AIDS
long-term effects
Pr EP efficacy
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
required
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
liver toxicity
lactic acidosis
bone density loss
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
treatment of HIV
prevention of HIV
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
|
gptkbp:bfsLayer
|
4
|